{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:30:23Z","timestamp":1790314223235,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jgar.2018.02.014","type":"journal-article","created":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T13:01:13Z","timestamp":1519477273000},"page":"72-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Antifungal susceptibility testing results of New Zealand yeast isolates, 2001\u20132015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species"],"prefix":"10.1016","volume":"14","author":[{"given":"Arthur J.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy P.","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2018.02.014_bib0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1473-3099(10)70218-8","article-title":"Emerging opportunistic yeast infections","volume":"11","author":"Miceli","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2018.02.014_bib0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2018.02.014_bib0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0002-9343(95)00010-0","article-title":"The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance","volume":"100","author":"Nguyen","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.jgar.2018.02.014_bib0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1128\/CMR.19.2.435-447.2006","article-title":"Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing","volume":"19","author":"Pfaller","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2018.02.014_bib0025","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/CMR.14.4.643-658.2001","article-title":"Antifungal susceptibility testing: practical aspects and current challenges","volume":"14","author":"Rex","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2018.02.014_bib0030","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1086\/342384","article-title":"Has antifungal susceptibility testing come of age?","volume":"35","author":"Rex","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.02.014_bib0035","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1128\/CMR.17.2.268-280.2004","article-title":"Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization","volume":"17","author":"Pfaller","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2018.02.014_bib0040","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1128\/JCM.40.10.3776-3781.2002","article-title":"Optimum testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study","volume":"40","author":"Espinel-Ingroff","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.drup.2010.09.002","article-title":"Wild-type MIC distributions, epidemiological cutoff valves and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods","volume":"13","author":"Pfaller","year":"2010","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jgar.2018.02.014_bib0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2011.01.004","article-title":"Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretation criteria","volume":"14","author":"Pfaller","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jgar.2018.02.014_bib0055","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.diagmicrobio.2011.03.002","article-title":"Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria","volume":"70","author":"Pfaller","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2018.02.014_bib0060","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement. Document M27-S3","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"10.1016\/j.jgar.2018.02.014_bib0065","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement. Document M27-S4","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.jgar.2018.02.014_bib0070","series-title":"Epidemiological cutoff values for antifungal susceptibility testing. Document M59Ed2","author":"Clinical and Laboratory Standards Institute","year":"2018"},{"key":"10.1016\/j.jgar.2018.02.014_bib0075","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1128\/JCM.00937-12","article-title":"Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012","volume":"50","author":"Pfaller","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0080","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1128\/AAC.02615-13","article-title":"Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole","volume":"58","author":"Espinel-Ingroff","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.014_bib0085","first-page":"30","article-title":"Antifungal susceptibility patterns of Candida","volume":"3","author":"Clark","year":"1996","journal-title":"Lablink (NZCDC)"},{"key":"10.1016\/j.jgar.2018.02.014_bib0090","first-page":"528","article-title":"Antifungal susceptibilities of Candida sp. in New Zealand","volume":"114","author":"Hill","year":"2001","journal-title":"N Z Med J"},{"key":"10.1016\/j.jgar.2018.02.014_bib0095","first-page":"U1060","article-title":"Antifungal susceptibility of non-albicans Candida species causing fingernail onychomycosis","volume":"117","author":"Upton","year":"2004","journal-title":"N Z Med J"},{"key":"10.1016\/j.jgar.2018.02.014_bib0100","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/jac\/dkx047","article-title":"Changing face of candidaemia in Australia","volume":"72","author":"Chapman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.02.014_bib0105","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1542\/peds.2008-2055","article-title":"Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients","volume":"123","author":"Blyth","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jgar.2018.02.014_bib0110","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1128\/JCM.01230-13","article-title":"Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method","volume":"51","author":"Cant\u00f3n","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0115","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1128\/AAC.01250-15","article-title":"Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method","volume":"59","author":"Espinel-Ingroff","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.014_bib0120","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. Document M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"10.1016\/j.jgar.2018.02.014_bib0125","series-title":"Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline. Document M44-A2","author":"Clinical and Laboratory Standards Institute","year":"2009"},{"key":"10.1016\/j.jgar.2018.02.014_bib0130","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1128\/JCM.03044-13","article-title":"Impact of new antifungal breakpoints on antifungal resistance in Candida species","volume":"52","author":"Fothergill","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0135","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2217\/fmb-2016-0099","article-title":"Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region","volume":"11","author":"Wang","year":"2016","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0140","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1128\/JCM.37.3.591-595.1999","volume":"37","author":"Espinel-Ingroff","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0145","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1128\/JCM.01840-06","article-title":"Comparative evaluation of Etest and Sensititre YeastOne panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents","volume":"45","author":"Alexander","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0150","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1128\/JCM.02316-09","volume":"48","author":"Cuenca-Estrella","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0155","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/JCM.42.2.718-721.2004","article-title":"Multicentre comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp","volume":"42","author":"Espinel-Ingroff","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0160","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1128\/JCM.01730-12","article-title":"Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne method","volume":"50","author":"Canton","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0165","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1111\/j.1439-0507.2011.02165.x","article-title":"Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-center study","volume":"55","author":"Schmalreck","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.jgar.2018.02.014_bib0170","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/JCM.01590-09","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp","volume":"48","author":"Pfaller","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0175","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1128\/JCM.02120-10","article-title":"Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin","volume":"49","author":"Pfaller","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.02.014_bib0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.diagmicrobio.2010.08.013","volume":"69","author":"Pfaller","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2018.02.014_bib0185","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1128\/AAC.00355-12","article-title":"Danish Fungaemia Study Group: Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints","volume":"56","author":"Arendrup","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.014_bib0190","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1128\/AAC.01519-13","article-title":"Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.014_bib0195","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1128\/AAC.02163-13","article-title":"Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates","volume":"58","author":"Eschenauer","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.014_bib0200","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1128\/JCM.02416-16","article-title":"Establishment and use of epidemiological cutoff values for molds and yeasts using the Clinical and Laboratory Standards Institute M57 standard","volume":"55","author":"Lockhart","year":"2017","journal-title":"J Clin Microbiol"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518300420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518300420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:53:31Z","timestamp":1761990811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716518300420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":40,"alternative-id":["S2213716518300420"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2018.02.014","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifungal susceptibility testing results of New Zealand yeast isolates, 2001\u20132015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2018.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}